An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
NCT ID: NCT06117891
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2023-11-27
2027-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Unresectable hepatocellular carcinoma (uHCC) is a type of liver cancer that cannot be treated with surgery.
In the past, sorafenib was the only approved first-line anti-cancer drug for people with uHCC. Regorafenib and other drugs were approved as second-line treatments for uHCC if a person could not take sorafenib or it stopped working for them.
Lately, another first-line (1L) treatment called immuno-oncology (IO) immune checkpoint inhibitor combination (1L-IO combo), like atezolizumab with bevacizumab (AB), has become the preferred choice of treatment. This is because of the meaningful impact on patient survival. 1L-IO combo are drugs that help the body's defense system recognize and kill cancer cells.
Since the other treatments were previously approved for use following sorafenib, the best order to take these treatments in following an 1L-IO combo is unknown.
To better understand and determine this order, more knowledge is needed about how well different treatments work in participants with uHCC who have been treated with AB or another 1L-IO combo.
The main purpose of this study is to learn more about how well different treatments work when given after first-line treatment with AB or another approved 1L-IO combo. To do this, researchers will collect data on how long the participants live (also called overall survival) from the start of any treatment given after the first-line treatment.
In addition, researchers will also collect the following information to learn more about the participants who will be given a different treatment after the 1L-IO combo:
* characteristics including age, sex, and race, and signs and symptoms of the participants over the duration of their first-line treatment
* the length of time from the first to the last dose (also called duration of therapy) of the treatments given after the 1L-IO combo
* the length of time until a participant's cancer worsens, or they die (also called progression free survival) from the start of the treatments given after the 1L-IO combo
* the number of participants whose tumor completely disappears or shrinks (also called overall tumor response) after taking the treatments given after the 1L-IO combo
* the sequence of treatments given after the 1L-IO combo Data will be collected from September 2023 to December 2026 and cover a period of around 3 years. The data will be collected using medical records or by interviewing the participants during their routine visits to the doctor.
Researchers will observe participants from the start of the treatment given after the 1L-IO combo until the end of their participation in the study.
In this study, only data from routine care will be collected. No visits or tests are required as part of this study.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
Patients with a diagnosis of uHCC treated with first-line AB or another approved 1L-IO combo and in whom a decision to treat with a second-line of systemic therapy has been made by the treating physician at the time of study enrollment
Atezolizumab
Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
Bevacizumab
Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
Durvalumab
Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
Tremelimumab,
Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
Bevacizumab
Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
Durvalumab
Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
Tremelimumab,
Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of uHCC, treated in a first-line setting with AB or another approved 1L-IO combo therapy.
* Decision to initiate treatment with a second-line systemic treatment was made as per investigator's routine treatment practice prior to study enrollment.
* Signed informed consent or (for patients under legal age) signed informed assent by the patient (where applicable) and signed informed consent by parents / legal guardian.
* No participation in an investigational program with interventions outside of routine clinical practice.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mercy Medical Center - Medline Healthcare Services LLC
Baltimore, Maryland, United States
University of Michigan Health System
Ann Arbor, Michigan, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
University Of Cincinnati Division Of Hematology Oncology - UC Health System
Cincinnati, Ohio, United States
Corporal Michael J Crescenz Department Of Veterans Affairs Medical Center
Philadelphia, Pennsylvania, United States
Einstein Medical Center
Philadelphia, Pennsylvania, United States
Many Locations
Multiple Locations, , Argentina
Many Locations
Multiple Locations, , Brazil
Many Locations
Multiple Locations, , China
Many Locations
Multiple Locations, , Colombia
Many Locations
Multiple Locations, , France
Many Locations
Multiple Locations, , Greece
Many Locations
Multiple Locations, , Italy
Many Locations
Multiple Locations, , Mexico
Many Locations
Multiple Locations, , Saudi Arabia
Many Locations
Multiple Locations, , South Korea
Many Locations
Multiple Locations, , Spain
Many Locations
Multiple Locations, , Taiwan
Many Locations
Multiple Locations, , Thailand
Many Locations
Multiple Locations, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for access to information about Bayer's transparency standards and Bayer studies.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22453
Identifier Type: -
Identifier Source: org_study_id